Rallybio vs Yarrow Bioscience
RLYB and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RLYB and YARW compare
Rallybio is the larger company, worth 2.2 times as much as Yarrow Bioscience ($82.3M against $37.9M).
Yarrow Bioscience grew revenue faster over the last twelve months (13.8% versus −35.6% for Rallybio).
Rallybio keeps more of each dollar of sales as profit, with a net margin of 6177% compared with −4646% at Yarrow Bioscience.
Yarrow Bioscience pays a dividend yielding 142%; Rallybio does not pay one.
Yarrow Bioscience scores higher on the StockData Score (11 against 10 for Rallybio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RLYB | YARW |
|---|---|---|
| Size and price | ||
| Market cap | $82.3M | $37.9M |
| Share price | $15.29 | $14.21 |
| Change, 1 year | 199% | −24.1% |
| Change, 5 years | −85.5% | −98.5% |
| Beta (5Y) | 0.01 | 2.07 |
| Employees | 14 | 10 |
| StockData Score | ||
| Total score | 10 | 11 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 3.4× | – |
| P/S | 190× | 66.6× (better) |
| P/B | 0.9× (better) | 1.7× |
| FCF yield | – | −87.3% |
| Fair value | – | $7.04 |
| Margin of safety | – | −102% |
| Growth | ||
| Revenue growth (TTM) | −35.6% | 13.8% (better) |
| Revenue growth, 5Y average | – | −51.4% |
| Profitability | ||
| Operating margin | −5581% | −5219% (better) |
| Net margin | 6177% (better) | −4646% |
| FCF margin | – | −5811% |
| Return on equity | 34.5% (better) | −86.9% |
| Return on invested capital | −718% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 28.87 (better) | 15.26 |
| Altman Z-score | 11.42 (better) | −33.58 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 142% |
| Shareholder yield | 0.00% | 142% (better) |
| Ownership | ||
| Held by institutions | – | 11.6% |
| Held by insiders | 72.6% | 82.1% |
| Insider net buying, 12 months | $4.2M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.6% | 29.7% |
Go deeper
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.